A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

NCT03459534 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia, Chronic Phase
CML, Chronic Phase
CML, Refractory
CML - Philadelphia Chromosome

Interventions

DRUG: Radotinib HCl

Sponsor

Il-Yang Pharm. Co., Ltd.